2021-08-16-世界卫生组织-Preferred_product_characteristics_for_vaccines_against_enterotoxigenic_Escherichia_coli_36页_1mb

报告摘要

WHO优选ETEC疫苗产品特性：全球健康战略的核心考量

迪arrhoeal diseases remain a leading cause of morbidity and mortality worldwide, particularly in children under five and LMICs. ETEC, a key bacterial pathogen causing diarrhoea, demands urgent vaccine development to address unmet public health needs. This analysis outlines WHO's preferred product characteristics (PPCs) for ETEC vaccines, emphasizing feasibility, efficacy, and equitable access.

1. Context and Burden:

Enterotoxigenic E. coli (ETEC) causes an estimated 220 million diarrhoea episodes globally, with 18,700–50,000 child deaths annually. It disproportionately affects infants in LMICs and travellers.
ETEC contributes significantly to long-term sequelae: stunting, cognitive impairment, and increased susceptibility to other infections, making vaccine development a priority for the Immunization Agenda 2030.

2. WHO Preferred Product Characteristics (PPCs):
The PPCs serve as strategic guidance for vaccine developers, funders, and policymakers, outlining essential attributes for ETEC vaccines suitable for LMIC use:

Parameter	Preferred Characteristics	Key Notes
Indication	Prevention of Moderate-to-Severe Diarrhoea (MSD) due to ETEC	Primary endpoint; includes reduction in mortality and morbidity, especially in infants under 24 months.
Target Population	Infants (6 months–5 years)	Focus on covering peak incidence through age-appropriate immunization schedules aligned with EPI programs.
Dose Regimen	At least two doses, potentially a booster	Schedule should provide early protection (by 9 months) and extend coverage up to 5 years. Align with existing vaccines where possible.
Safety & Efficacy	Comparable to routine WHO vaccines, ≥60% efficacy	Must demonstrate a favourable safety profile and efficacy based on laboratory-confirmed cases in LMIC settings.
Route & Presentation	Oral or injectable, low-dose formulations	Prioritize easier administration (e.g., oral vaccines avoid cold chain complexities). Use small-volume vials to reduce waste.
Stability	≥2 years at 2–8°C for liquid vaccines	Multi-dose containers and thermostable formulations recommended for LMIC infrastructure.
Delivery	Integration into national immunization programs	Co-formulation with other EPI vaccines (e.g., rotavirus, typhoid) encouraged to improve uptake and cost-effectiveness.

3. Economic & Access Considerations:

Affordability: Vaccines must be cost-effective and accessible, especially in LMICs, necessitating transparent pricing and public-private partnerships.
Market Realities: While high-income travellers represent a market, focus must remain on LMIC populations to maximize public health impact and reduce antibiotic misuse driving AMR.

4. Challenges & Future Directions:

Consensus Development: Standardized measurement of MSD and severity scores (e.g., similar to rotavirus trials) is needed for robust trial comparability.
Technology Innovation: Multicomponent vaccines combining antigens or delivery routes (e.g., injectable for mucosal immunity) are preferred for broad strain coverage and simplified administration.
Research & Funding: Accelerating ETEC vaccine development requires sustained investment, especially in clinical trials addressing real-world efficacy and long-term burden.

5. Global Value Proposition:

An effective ETEC vaccine offers tangible benefits: reducing diarrhoea-related deaths, mitigating AMR spread, enhancing child development, and alleviating healthcare system burdens. Cost-effectiveness models suggest substantial public health ROI.

Conclusion:
The PPCs provide a critical framework for prioritizing ETEC vaccine development, balancing scientific feasibility with practical implementation in resource-constrained settings. Achieving equitable global vaccine access demands coordinated efforts from developers, funders, and policymakers to address LMIC-specific barriers like cold chain limitations and programmatic integration.

展开完整摘要